Not exact matches
In an efficacy study involving
nonhuman primates that was specifically designed to evaluate the efficacy of AVI - 7288 after delayed treatment, a
dose of 15 mg per kilogram per day for 14 days starting at 24, 48, and 96 hours after viral challenge provided 83 %, 100 %, and 83 % protection, respectively.
Led by Bavari and Travis Warren, Ph.D., the USAMRIID team performed a series of studies involving a lethal challenge with Marburg virus
in nonhuman primates to determine the efficacious
dose and regimen of AVI - 7288, as well as to characterize the drug exposures
in animals that produced efficacy.
Tests
in mice and
nonhuman primates had shown TGN1412 to be safe, but when it was injected into humans —
in a
dose less than 1/500 of what was given to monkeys — it caused a massive release of infection - fighting T cells that overstimulated the patients» immune systems, resulting
in multiple organ failure.
In nonhuman primates that received ALN - TTR01 in a single dose of 1.0 mg per kilogram, the mean percent transthyretin knockdown at the nadir level (7 days after administration) was approximately 50 %, with recovery to the baseline level by day 28 (Fi
In nonhuman primates that received ALN - TTR01
in a single dose of 1.0 mg per kilogram, the mean percent transthyretin knockdown at the nadir level (7 days after administration) was approximately 50 %, with recovery to the baseline level by day 28 (Fi
in a single
dose of 1.0 mg per kilogram, the mean percent transthyretin knockdown at the nadir level (7 days after administration) was approximately 50 %, with recovery to the baseline level by day 28 (Fig.